Liposarcoma - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 162 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liposarcoma - Pipeline Review, H2 2016, provides an overview of the Liposarcoma (Oncology) pipeline landscape.

Liposarcoma is a malignant tumor of fatty tissue. Symptoms include noticeable lump or swelling, pain, weight loss and abdominal pain. Predisposing factors include age, chemical exposure and radiation exposure. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liposarcoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liposarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liposarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Liposarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 10, 3 and 2 respectively.Liposarcoma.

Liposarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Liposarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Liposarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liposarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liposarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Liposarcoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liposarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liposarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Liposarcoma Overview 7
Therapeutics Development 8
Pipeline Products for Liposarcoma - Overview 8
Liposarcoma - Therapeutics under Development by Companies 9
Liposarcoma - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Liposarcoma - Products under Development by Companies 13
Liposarcoma - Companies Involved in Therapeutics Development 14
Adaptimmune Therapeutics Plc 14
Amgen Inc 15
Cellceutix Corp 16
Eli Lilly and Company 17
Horizon Pharma Plc 18
Immune Design Corp 19
Karyopharm Therapeutics Inc 20
Merck & Co Inc 21
Mirati Therapeutics Inc 22
Novartis AG 23
Pfizer Inc 24
Liposarcoma - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 29
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
abemaciclib - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
AMG-232 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
CMB-305 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
everolimus - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
GSK-3377794 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
HDM-201 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
interferon gamma-1b - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Kevetrin - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
palbociclib - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
pazopanib hydrochloride - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
pembrolizumab - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
ribociclib succinate - Drug Profile 130
Product Description 130
Mechanism Of Action 130
R&D Progress 130
selinexor - Drug Profile 135
Product Description 135
Mechanism Of Action 135
R&D Progress 135
sirolimus - Drug Profile 152
Product Description 152
Mechanism Of Action 152
R&D Progress 152
sitravatinib - Drug Profile 153
Product Description 153
Mechanism Of Action 153
R&D Progress 153
Vimo-101 - Drug Profile 156
Product Description 156
Mechanism Of Action 156
R&D Progress 156
Liposarcoma - Dormant Projects 157
Liposarcoma - Discontinued Products 158
Liposarcoma - Product Development Milestones 159
Featured News & Press Releases 159
Nov 09, 2016: Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma 159
Aug 03, 2016: Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR T-cell Therapy in Myxoid Round Cell Liposarcoma 159
Aug 03, 2016: Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR T-cell Therapy in Myxoid Round Cell Liposarcoma 159
Appendix 161
Methodology 161
Coverage 161
Secondary Research 161
Primary Research 161
Expert Panel Validation 161
Contact Us 161
Disclaimer 162

List of Tables

Number of Products under Development for Liposarcoma, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Liposarcoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 14
Liposarcoma - Pipeline by Amgen Inc, H2 2016 15
Liposarcoma - Pipeline by Cellceutix Corp, H2 2016 16
Liposarcoma - Pipeline by Eli Lilly and Company, H2 2016 17
Liposarcoma - Pipeline by Horizon Pharma Plc, H2 2016 18
Liposarcoma - Pipeline by Immune Design Corp, H2 2016 19
Liposarcoma - Pipeline by Karyopharm Therapeutics Inc, H2 2016 20
Liposarcoma - Pipeline by Merck & Co Inc, H2 2016 21
Liposarcoma - Pipeline by Mirati Therapeutics Inc, H2 2016 22
Liposarcoma - Pipeline by Novartis AG, H2 2016 23
Liposarcoma - Pipeline by Pfizer Inc, H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Liposarcoma - Dormant Projects, H2 2016 157
Liposarcoma - Discontinued Products, H2 2016 158